Hosts Nancy Reau and Kimberly Brown are joined by Mary Rinella to discuss the evolving MASH treatment landscape with GLP-1s and FGF21s in development.
Mary (Maru) Rinella, MD
Advertisement
Mary (Maru) Rinella, MD, is a professor of medicine, director of the Metabolic and Fatty Liver Program, and director of Clinical Trials at the University of Chicago.
Articles by Mary (Maru) Rinella, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study
2
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
3
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
4
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
5